Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors

Area of Science:

• Oncology
• Biochemistry

Background:

• Folate is essential for cell turnover and cancer proliferation.
• Folate receptor (FR) and its subtype FRα are implicated in carcinogenesis.
• FRα is overexpressed in several cancer types, suggesting its role as a biomarker.

Purpose of the Study:

• To discuss the role of FR in cancer biology.
• To explore FR as a biomarker for cancer diagnosis, progression, and prognosis.
• To review pharmacologic inhibitors targeting FR.

Main Methods:

• Literature review of studies on folate receptor in cancer.
• Analysis of FR expression in various cancers (gastrointestinal, gynecological, breast, lung, head and neck).
• Examination of traditional antifolate chemotherapies and emerging FR-targeted therapies.

Main Results:

• FR and FRα show potential as biomarkers for cancer.
• Several cancer types overexpress FR, correlating with disease state.
• Antifolate drugs like methotrexate and pemetrexed exhibit anticancer activity.

Conclusions:

• FRα is a promising biomarker for cancer diagnosis and prognosis.
• Targeting FR represents a growing area for cancer pharmacotherapy.
• FR-targeted therapies offer a new avenue alongside traditional antifolate treatments.